Stockreport

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders [Yahoo! Finance]

Protagenic Therapeutics, Inc.  (PTIX) 
US:NASDAQ Investor Relations: protagenic.com/investors
PDF leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The company has reached an [Read more]